Table 4.

Patient characteristics

Patient	Age, years/sex	Diagnosis	CD33, %	P‐gp, %	MRP	Apoptosis, %
1	46/F	M3	97.7	2.3	ND	47
2	78/M	M6	53.9	2.8	ND	ND
3	36/M	M2	73.1	0.9	ND	10
4	88/M	M0	56.6	0.4	–	28
5	41/M	M2	71.8	0.7	–	58
6	63/M	MPD‐LT	80.8	2.2	ND	10
7	71/M	MPD‐LT	88.4	0.2	ND	ND
8	17/M	M1	99.4	0.9	ND	ND
9	70/M	M2	89.7	2.1	ND	48
10	71/M	M2	74.3	–	–	ND
11	75/M	M2	97.4	–	–	18

Flow cytometric analyses were carried out to detect the expression of CD33 and P‐glycoprotein (P‐gp) in patient samples (nos. 1–9). In nos.10 and 11, P‐gp was determined using real‐time RT‐PCR. Multidrug resistance protein (MRP) was evaluated for its transcript level using real‐time RT‐PCR in nos. 4, 5, 10, and 11. Apoptotic cell death was determined by Hoechst staining after the cells had been incubated with gemtuzumab ozogamicin (10 μg/mL) for 72 h. M0–6, French–American–British classification for acute leukemia; MPD‐LT, leukemic transformation from myeloproliferative disease; ND, not determined.